Rationale and clinical results of inhibiting interleukin-5 for the treatment of severe asthma
Severe asthma is responsible for considerable morbidity and a high proportion of the healthcare costs attributable to asthma. Management is not straightforward as the clinical, pathological and physiological features are heterogeneous and the relationships between these features are poorly understoo...
Հիմնական հեղինակներ: | Berair, R, Pavord, I |
---|---|
Ձևաչափ: | Journal article |
Լեզու: | English |
Հրապարակվել է: |
2013
|
Նմանատիպ նյութեր
-
Rationale and clinical results of inhibiting interleukin-5 for the treatment of severe asthma.
: Berair, R, և այլն
Հրապարակվել է: (2013) -
Interleukin-5 inhibitors for severe asthma: Rationale and future outlook.
: Shrimanker, R, և այլն
Հրապարակվել է: (2017) -
Evidence for the efficacy and safety of anti- interleukin-5 treatment in the management of refractory eosinophilic asthma
: Xue, L, և այլն
Հրապարակվել է: (2015) -
Interleukin-5 in the Pathophysiology of Severe Asthma
: Corrado Pelaia, և այլն
Հրապարակվել է: (2019-12-01) -
Elevated sputum interleukin-5 and submucosal eosinophilia in obese individuals with severe asthma.
: Desai, D, և այլն
Հրապարակվել է: (2013)